Dihexa

Dihexa (PNB-0408), also known as ATH-1001, is an experimental, peptide-derived compound developed at Washington State University from the naturally occurring hormone fragment angiotensin IV. Chemically identified as N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide, Dihexa was engineered to improve metabolic stability, oral activity, and penetration into the brain. It has attracted significant research interest because early animal studies demonstrated improvements in learning and memory alongside changes in neuronal connectivity. Unlike traditional cognitive-enhancing medications that primarily affect neurotransmitter concentrations, Dihexa is proposed to influence the formation and maintenance of synapses—the connections through which neurons communicate.

Dihexa has been investigated for potential applications in Alzheimer’s disease, neuroplasticity, neuronal injury, and age-associated cognitive decline. Its proposed mechanism involves modulation of hepatocyte growth factor (HGF) and its receptor c-MET, which participate in cellular survival and growth-related signaling. However, major studies supporting this mechanism were retracted in 2025 because of falsified or fabricated experimental data, creating significant uncertainty about the original findings. Separate animal studies continue to provide preliminary evidence of neurological activity, but no controlled human trial has demonstrated that Dihexa improves cognition, restores synapses, prevents dementia, or can be administered safely. It remains an unapproved investigational compound with potentially significant long-term safety concerns.

Dihexa was designed to influence neuronal connectivity and memory-related signaling through mechanisms different from traditional neurotransmitter-based medications. Its most widely discussed mechanism involves modulation of hepatocyte growth factor (HGF) and the c-MET receptor, although key supporting research was retracted in 2025.

1. HGF/c-MET Signaling

• Hepatocyte growth factor (HGF) is a signaling protein involved in cellular survival, migration, development, and tissue repair.
• Its receptor, c-MET, is a receptor tyrosine kinase that activates several intracellular growth and survival pathways.
• Dihexa was originally proposed to bind HGF and enhance its ability to activate c-MET.
• However, the central 2014 study demonstrating this interaction was retracted in 2025 because of falsified or fabricated data.
• Direct HGF binding and the precise c-MET-dependent mechanism should therefore be regarded as unconfirmed rather than established.

2. Synaptogenesis: Forming Neural Connections

• Synaptogenesis is the process through which neurons develop new functional connections.
• Synapses help support learning, memory formation, and communication across neuronal networks.
• Early experiments associated Dihexa exposure with increased dendritic spine formation and synaptic connectivity.
• The principal mechanistic paper supporting these findings was retracted, and independent confirmation remains necessary.

3. PI3K/AKT Signaling

• The PI3K/AKT pathway participates in cellular survival, metabolism, inflammation, and growth-related signaling.
• A separate 2021 study investigated Dihexa in transgenic mice modeling Alzheimer's-related pathology.
• Researchers observed changes in PI3K/AKT signaling alongside improvements in spatial memory performance.
• These results suggest additional biological activity but do not conclusively establish the compound's direct molecular target.

4. Synaptic Protein Regulation

• Synaptophysin is a protein associated with synaptic vesicles and is commonly used as a marker of neuronal connections.
• In APP/PS1 mice, Dihexa treatment increased synaptophysin expression compared with untreated disease-model animals.
• Researchers also reported increased neuronal cell counts using histological measurements.
• These observations suggest potential effects on synaptic maintenance but do not establish functional synapse regeneration in humans.

5. Neuroinflammation Regulation

• Chronic neuroinflammation is associated with several neurological and neurodegenerative disorders.
• Animal research reported reduced expression of the inflammatory cytokines IL-1 beta and TNF-alpha following Dihexa exposure.
• The same study reported increased IL-10, a cytokine involved in controlling inflammatory responses.
• Changes in microglial and astrocyte markers were also observed.

6. Metabolic Stability and Brain Penetration

• Natural angiotensin IV is rapidly degraded and has limited ability to enter the central nervous system.
• Dihexa was chemically modified to improve stability, lipid solubility, and potential blood-brain barrier penetration.
• Preclinical research describes oral activity and central nervous system exposure.
• Human absorption, bioavailability, brain exposure, and elimination half-life have not been established.

7. Structural Relationship to Other Angiotensin IV Analogues

• Dihexa is derived from a shortened angiotensin IV-related peptide structure.
• Its chemical modifications were designed to overcome the poor pharmacokinetics of earlier compounds.
• It is distinct from angiotensin IV itself and from conventional drugs that block angiotensin receptors to lower blood pressure.

The Key Difference: Dihexa is not an approved cognitive enhancer or a proven brain-regeneration treatment. Although animal experiments support continued investigation, its exact molecular mechanism remains uncertain following the retraction of major HGF/c-MET studies.

Dihexa has attracted scientific interest because early animal research suggests it may influence memory, neuronal connectivity, and cellular processes associated with neurological recovery. Its ability to potentially modify synapse-related biology distinguishes it from conventional nootropic compounds.

• Memory Formation: Animal experiments have reported improvements in spatial learning and memory-related tasks.
• Synaptogenesis: Laboratory research identified changes in dendritic spine development and synaptic protein expression.
• Alzheimer's Disease: Researchers are investigating whether Dihexa can influence neuronal loss, synaptic dysfunction, and inflammation in experimental disease models.
• Neuroplasticity: Its proposed effects on neuronal connectivity provide a rationale for studying brain adaptation following injury.
• HGF/c-MET Biology: The compound is associated with research into this growth-factor pathway, although direct mechanistic evidence requires revalidation.
• Neuroinflammation: Mouse studies reported changes in inflammatory cytokines and glial-cell markers.
• Brain Injury: Preliminary experimental work has explored HGF/MET-related interventions in traumatic brain injury models.
• Hearing Protection: Zebrafish studies have investigated whether Dihexa can protect sensory hair cells from antibiotic-related injury.
• Drug Development: Dihexa helped inspire development of the related pharmaceutical compound fosgonimeton, which has undergone human clinical testing.

Research Limitation: Interest in these pathways does not establish therapeutic benefits. Direct human evidence is absent, and the retraction of several influential papers reduces confidence in the compound's originally proposed mechanism.

Preclinical studies have reported several potentially important biological effects of Dihexa. These observations are limited to animal and laboratory models, and some of the most widely cited early mechanistic findings have been retracted.

• Spatial Memory: A 2021 mouse study demonstrated improved performance in Morris water maze testing following Dihexa exposure.
• Synaptic Protein Expression: APP/PS1 mice receiving Dihexa showed increased synaptophysin expression.
• Neuronal Cell Preservation: Researchers observed improved neuronal histological measurements in treated Alzheimer's-model mice.
• Reduced Neuroinflammation: Experimental treatment was associated with lower IL-1 beta and TNF-alpha and higher IL-10.
• PI3K/AKT Signaling: Animal experiments implicated changes in the PI3K/AKT cellular survival pathway.
• Learning and Memory in Rats: Earlier research reported improved cognition in aged rats and animals with experimentally induced memory impairment, although one foundational study carries a formal notice of concern.
• Sensory Hair-Cell Protection: Zebrafish experiments reported protection against neomycin- and gentamicin-related hair-cell injury.
• Neuroplasticity: Experimental synapse-related findings provide a rationale for further research, but the most prominent HGF/c-MET mechanistic study was retracted.

Notable Alzheimer's Model Finding: A 2021 study investigated Dihexa at 1.44 and 2.88 mg/kg in APP/PS1 transgenic mice over three months. Researchers reported improvements in spatial memory testing, increased synaptophysin expression, improved neuronal histological measurements, and reduced neuroinflammatory markers.

Important Study Limitation: The 2021 publication contains conflicting descriptions of the administration route, referring to both intragastric and intraperitoneal delivery. This inconsistency limits confidence in interpreting the dosing protocol.

Notable Hearing Research Finding: A 2015 study using larval zebrafish found that Dihexa protected lateral-line sensory hair cells against certain aminoglycoside antibiotics. This does not establish prevention or reversal of hearing loss in humans.

Historical Potency Claim: Dihexa has frequently been described as ten million times more potent than BDNF in promoting synapse formation. This refers to a narrow experimental comparison, not a demonstrated ten-million-fold improvement in memory, cognition, or overall neuroprotection. Given the research-integrity concerns surrounding foundational studies, this claim should not be presented as an established measure of clinical potency.

Related Pharmaceutical Research: Fosgonimeton (ATH-1017) is a related prodrug designed to produce Dihexa as its active metabolite. In its Phase 2/3 Alzheimer's disease trial, fosgonimeton did not meet its primary or secondary efficacy endpoints. The result does not directly establish Dihexa's effectiveness or ineffectiveness.

Human Evidence Limitation: No published controlled human trial has demonstrated that Dihexa improves memory, restores neuronal connections, treats Alzheimer's disease, prevents dementia, or accelerates neurological recovery.

Research Perspective: Dihexa has demonstrated promising effects in selected animal models, but its mechanism, clinical effectiveness, and long-term safety remain uncertain. The 2025 retractions make independent replication especially important.

Dihexa has been investigated in animal models using experimental oral and injectable formulations, but no human clinical trial has established a safe or effective dose, administration route, or treatment schedule. Most human dosing information circulating online comes from research vendors and nootropic communities rather than controlled clinical research.

Published Research and Community-Reported Dosing

Administration Considerations:

• Oral Administration: Dihexa was chemically designed to improve oral activity, and preclinical research reported effects following oral exposure. Human oral absorption and bioavailability remain unknown.
• Subcutaneous Administration: Described in experimental communities, but no validated human injectable formulation or clinical pharmacokinetic study exists.
• Intranasal Administration: Sometimes promoted as a method of delivering peptides toward the central nervous system, but Dihexa-specific human absorption and brain delivery have not been established.
• Sublingual Administration: Occasionally discussed as an alternative route, without reliable human pharmacokinetic evidence.
• Frequency: Daily administration is common in animal experiments and informal community descriptions, but no human frequency has been validated.
• Timing: Morning administration and separation from meals are community conventions rather than evidence-based requirements.
• Half-Life: No published human study has established Dihexa's elimination half-life, duration of brain exposure, or accumulation profile.
• Formulation: Dihexa is highly lipophilic and has limited water solubility. Simple bacteriostatic-water recipes cannot be assumed to produce a stable, sterile, or accurately concentrated injectable preparation.
• Storage: Research-market storage recommendations vary, and no validated universal home-storage period exists for reconstituted Dihexa.
• Human Dose Extrapolation: Multiplying mouse milligram-per-kilogram doses by human body weight does not establish a safe or effective human amount.

Important Distinction: The 2021 mouse study provides quantitative animal exposure data, but the publication inconsistently describes intragastric and intraperitoneal administration. Its reported amounts should not be treated as a validated oral or injectable human protocol.

Research Perspective: No human dose-finding study, maximum tolerated dose, or validated formulation exists for Dihexa. The community-reported amounts are included for educational comparison, not as administration recommendations.

No clinically validated treatment cycle or washout period exists for Dihexa. Published animal studies examined experimental exposure periods, while community protocols frequently describe several weeks of administration followed by treatment-free intervals.

• Early Rat Research: Evaluated learning, memory, and neurological measurements over study-specific experimental periods.
• 2021 Alzheimer's Mouse Research: Investigated treatment extending approximately three months.
• Community Short Cycles: Six weeks of administration followed by several weeks off are sometimes discussed.
• Common Community Cycles: Eight weeks of administration followed by approximately four weeks off appear frequently in informal protocols.
• Extended Community Cycles: Ten to twelve weeks are sometimes described.
• Community Washout Periods: Three to six weeks are discussed without clinical validation.
• Repeated Courses: No human evidence establishes the effectiveness or safety of repeated courses over months or years.
• Long-Term Exposure: Chronic neurological, reproductive, cardiovascular, and cancer-related risks remain insufficiently characterized.

Receptor Tolerance and Downregulation: Community sources sometimes claim that c-MET receptor downregulation begins after four to six weeks and that a washout restores responsiveness. No published human Dihexa study validates this timeline or establishes that cycling prevents tolerance.

Persistence of Neural Changes: Claims that Dihexa permanently establishes beneficial synaptic connections after treatment discontinuation have not been demonstrated in humans.

Research Consideration: Neuroplasticity is influenced by learning, experience, sleep, disease processes, and ongoing neural activity. Increasing a synaptic marker during an animal experiment does not establish permanent improvements in memory.

Important Limitation: No evidence establishes an optimal course length, maintenance strategy, or long-term safety limit for Dihexa. The described community schedules are informal conventions rather than clinically supported treatment plans.

Dihexa is sometimes discussed alongside other experimental neuropeptides, nootropics, and compounds that influence neuroplasticity or cellular signaling. These combinations have not been validated in controlled human clinical studies.

Research Perspective: Combining multiple experimental compounds that influence neural growth or plasticity does not establish superior cognition. Potential interactions involving cellular proliferation, neurological excitability, and growth-factor signaling remain unstudied.

Important Distinction: Dihexa's proposed HGF/c-MET activity creates particular concerns about combining it with substances that influence growth-related signaling or medications intended to inhibit c-MET in cancer treatment.

Dihexa has not undergone adequate human clinical safety testing. Its adverse-effect profile is therefore largely unknown. Community descriptions include neurological and gastrointestinal complaints, but reliable incidence rates cannot be established.

Important Growth-Factor Concern: HGF/c-MET signaling is involved in both normal tissue repair and several forms of cancer biology. Because Dihexa has been proposed to influence this pathway, its long-term effects on tumor growth or progression require careful investigation.

Important Evidence Qualification: Activation of a cancer-associated signaling pathway does not prove that a compound causes cancer. However, the absence of long-term human safety and carcinogenicity studies means this theoretical risk cannot be dismissed.

Research-Integrity Concern: The retraction of important Dihexa mechanism papers further limits confidence in predicting its biological effects and potential adverse reactions.

Human Evidence Limitation: No controlled human safety study establishes the frequency of headache, anxiety, insomnia, gastrointestinal symptoms, or serious adverse events following Dihexa exposure.

Research Perspective: Dihexa's ability to influence growth-related or neuroplasticity pathways makes detailed toxicology and long-term safety research especially important before clinical use could be justified.

No FDA-approved contraindication profile exists for Dihexa because it has not completed human clinical development. Its proposed influence on HGF/c-MET signaling and neuronal plasticity creates several areas of particular concern.

• Active Cancer: HGF/c-MET signaling contributes to cellular proliferation, migration, and several cancer-related processes. The effects of Dihexa in people with malignancy remain unknown.
• History of Cancer: Potential effects on cancer recurrence and abnormal cellular growth have not been investigated adequately.
• Precancerous Conditions: Theoretical concerns about growth-factor signaling warrant particular caution, although specific human risks have not been quantified.
• Brain Tumors: Effects on tumor-related growth pathways within the central nervous system remain unknown.
• Pregnancy and Breastfeeding: Reproductive, fetal-development, and lactation safety data are unavailable.
• Children and Adolescents: Effects on the developing nervous system have not been established.
• Epilepsy / Seizure Disorders: Changes in neuronal signaling could have unpredictable effects; seizure-related safety has not been characterized.
• Bipolar Disorder / Severe Anxiety: Human effects on mood, arousal, and behavioral regulation remain unknown.
• Neurological Disease: Dihexa has not been clinically demonstrated to treat Alzheimer's disease, Parkinson's disease, stroke, or traumatic brain injury.
• Retinal or Sensory Disorders: Growth-factor and neuronal signaling effects have not been adequately evaluated in human retinal or sensory tissues.
• Kidney or Liver Disease: Human metabolism, elimination, and organ safety remain uncharacterized.
• Psychiatric Medications: Interactions with stimulants, antidepressants, antipsychotics, and other centrally acting drugs remain unknown.
• Oncology Medications: Potential interactions with c-MET inhibitors and other cancer therapies require particular concern.
• Concurrent Experimental Neuropeptides: Combining multiple unapproved neurotrophic compounds may increase uncertainty about adverse effects.
• Unregulated Products: Research-market formulations may contain incorrect concentrations, impurities, or unsuitable ingredients.

Regulatory Caution: Dihexa is not FDA-approved for Alzheimer's disease, cognitive enhancement, dementia prevention, nerve regeneration, brain injury recovery, or any other therapeutic indication. No validated human treatment protocol exists.

Important Distinction: Cancer-related and neurological risks are theoretical concerns rather than confirmed adverse outcomes from human Dihexa trials. The lack of clinical testing means the risks cannot be reliably quantified.

Research Integrity: Multiple foundational papers involving Dihexa-related HGF/c-MET mechanisms were retracted in April 2025. This uncertainty should be considered when evaluating claims about clinical efficacy and safety.

Medical Consideration: Progressive memory loss, neurological deficits, or suspected dementia require established medical evaluation. Dihexa has not demonstrated an ability to substitute for approved neurological treatment.

Dihexa research has focused on memory performance, synaptic proteins, cellular signaling, and neuroinflammatory responses. No validated clinical monitoring protocol exists for Dihexa administration in humans.

Research Consideration: Synaptophysin, HGF/c-MET activity, and PI3K/AKT signaling are experimental measurements. They are not routine clinical tests for evaluating whether Dihexa has created functional neural connections.

Cancer Safety Consideration: No validated cancer-screening test or biomarker panel has been established specifically to detect potential Dihexa-related complications. Normal laboratory results would not rule out long-term growth-related risks.

Cognitive Testing Consideration: Improvements on memory tests can be influenced by practice effects, sleep, motivation, medication changes, and underlying health. Controlled study designs are necessary to distinguish true treatment effects from other influences.

Important Limitation: No monitoring schedule, laboratory marker, imaging study, or neurological test has been validated to establish the safety or effectiveness of Dihexa in humans.